National Science Foundation

Remedium Bio is a Boston-based gene therapy company dedicated to developing curative treatments for various debilitating conditions. The company employs a modular approach to research and development, utilizing established technologies in innovative ways to address well-understood disease mechanisms. By focusing on clinically validated molecules and targeted treatment strategies, Remedium Bio aims to create effective therapies for conditions within rheumatology, endocrinology, and neurology. Its pipeline includes promising gene therapy candidates designed to tackle a wide range of diseases, including immune and age-related disorders.

GENASSIST is a genetics company that provides assisted reproductive technology genetic consultation and testing services.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

Canomiks operates a genomics and artificial intelligence-based technology platform that focuses on testing and certifying the biological efficacy and safety of ingredients and formulations. Its services cater to the functional food and beverage, dietary supplement, and skincare industries, allowing companies to develop safe and effective products efficiently. By leveraging omics science, data analytics, machine learning, and bioinformatics, Canomiks streamlines the validation process for product efficacy, ultimately enabling clients to enhance product quality while reducing development time and costs. The company's long-term vision is to actualize the concept of food as medicine.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Soil Culture Solutions, LLC, founded in 2014 and headquartered in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees that utilize CRISPR editing techniques to enhance resistance to severe diseases affecting the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to combat these critical infections in citrus crops.

Biochip Labs, founded in 2019 and headquartered in Cleveland, Ohio, specializes in laboratory testing services for blood disorders, particularly sickle cell disease and thalassemia. The company offers a variety of proprietary microfluidic biomarker assays that assess blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the efficacy of emerging targeted and curative therapies, allowing clinicians to effectively monitor patient responses to treatment. By focusing on accurate and high-quality testing, Biochip Labs aims to advance the understanding and management of blood disorders.

Sequegenics operates a fully automated cloud platform designed to detect structural variants and other complex types of genetic variations. By employing a novel approach that utilizes low-pass long-read next-generation sequencing (NGS), the platform processes raw DNA sequence data efficiently. This innovation allows clients to significantly reduce the time and costs associated with variant calling while enhancing scalability and turnaround times. Sequegenics aims to streamline the detection of complex genetic variations, thereby facilitating more effective genetic analysis for its users.

Kodikaz Therapeutic Solutions is focused on advancing cancer treatment by developing targeted therapies aimed at eradicating cancers while minimizing side effects. The company utilizes its innovative Zip-Code™ Technology platform, a first-in-class delivery system that facilitates cell-specific genomic transfer for both RNA and DNA applications. Rooted in discoveries from human cancers, this platform addresses the limitations associated with traditional viral delivery methods, providing a more effective and safer alternative. Kodikaz's research generates valuable in-vitro and in-vivo data across various oncological applications, including pancreatic, myeloma, and colorectal cancers, supporting the development of curative gene transfer technologies.

Ancilia Biosciences focuses on developing engineered bacterial therapies aimed at treating diseases associated with the microbiome. The company specializes in creating virus-resistant live bacterial products that modulate the human microbiome, specifically targeting the viral components within the gut microbiome. By concentrating on healthy gut bacteria and their predatory phages, Ancilia engineers resistant bacterial strains to combat diseases. Its innovative approach includes the development of a new class of live biotherapeutics that allows medical professionals to target specific phages or viruses that induce lysis, with applications in immunology and oncology.

Stellate DNA, founded in 2020 and based in Cambridge, Massachusetts, specializes in proprietary DNA donor technology aimed at synthesizing and producing single-strand DNA donors. The company employs a clonal synthesis platform rather than traditional chemical methods, enabling the production of customizable gene knock-in payloads. This approach ensures well-controlled production at microgram to milligram scales, assisting medical professionals in achieving minimal mutation rates and maintaining sequence uniformity. Through its innovative technology, Stellate DNA addresses the demands of the biotechnology sector while supporting advancements in genetic research and therapeutic applications.

Tacit Therapeutics is a biotechnology company focused on developing RNA-targeted treatments to address genetic diseases. Founded in 2021 and based in South San Francisco, California, the company utilizes pre-existing components of human cells to create innovative, non-immunogenic methods for repairing mutated genes. By offering a broadly applicable approach to gene modification, Tacit Therapeutics aims to provide effective solutions for genetic conditions that were previously deemed untreatable, thereby enabling advancements in the treatment of devastating diseases.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Oculogenex is a biopharmaceutical company based in La Habra, California, established in 2020. The company specializes in developing gene therapies specifically aimed at treating retinal disorders. Its innovative approach involves ocular regenerative gene therapy that protects retinal pigment epithelial cells from oxidative stress-induced damage, which is a contributing factor to macular degeneration. By focusing on these therapies, Oculogenex aims to enhance the detection and treatment of various retinal disorders, ultimately supporting researchers in advancing novel drug solutions in this critical area of healthcare.

Talus Bio is a biotech startup focused on drug discovery, particularly in the development of therapies targeting gene regulators for cancer treatment. The company utilizes a data-enabled platform that combines functional proteomics, automated biology, and machine learning to address the challenges associated with cancer transcription factors. Its proprietary MARMOT platform employs advanced techniques such as AI, quantitative proteomics, synthetic chemistry, and computational biology to design and analyze small-molecule drugs and proteins. This innovative approach aims to enhance drug development processes in the oncology sector, facilitating advancements in gene regulation and contributing to more effective cancer therapies.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Cobio Diagnostics is a biotechnology company based in Golden, Colorado, founded in 2016. The company specializes in developing diagnostics aimed at rapid bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology can identify specific bacterial species and determine the most effective antibiotic treatment in under five hours. This innovative approach provides a faster and more targeted alternative to traditional diagnostic methods, allowing healthcare providers to make quicker and more informed decisions regarding antibiotic treatment for patients with bacterial infections.

CasTag Biosciences is focused on advancing cell biology and regenerative medicine through innovative tools that enhance the analysis of endogenous proteins. By developing adeno-associated virus kits, the company aims to expedite scientific discovery and empower researchers to investigate novel genes across various experimental models. Utilizing a unique two-vector, clustered regularly interspaced short palindromic repeats-based gene editing technique known as homology-independent universal genome engineering, CasTag's products enable the modification of entire panels of proteins within cells and tissues, thereby facilitating a deeper understanding of biological processes.

CO2 Sync, founded in 2019 and based in Cody, Wyoming, specializes in the development of genomically optimized plants aimed at achieving specific desired traits. The company operates in stealth mode, focusing on innovative agricultural solutions to enhance plant performance and adaptability.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

Acrigen Biosciences focuses on enhancing the safety and efficacy of gene editing technologies, particularly those based on the CRISPR-Cas system. Founded in 2019 and headquartered in Berkeley, California, the company develops innovative solutions that aim to produce effective in vivo drug therapies to combat various diseases. Acrigen's proprietary technologies include Acro proteins that regulate the CRISPR-Cas gene editing process and an advanced bioinformatics discovery software platform that identifies suitable CRISPR systems for human therapeutic applications. Through these advancements, Acrigen Biosciences seeks to improve the precision, efficacy, and safety of genetic therapies, ultimately contributing to the potential prevention and cure of debilitating diseases.

Inherent Biosciences is a molecular diagnostics company focused on transforming the trial and error approach in medicine by leveraging insights from epigenetics. The company aims to provide clarity on complex health issues by identifying dysregulation across multiple genes and pathways, which informs personalized treatment strategies. Inherent Biosciences develops innovative therapies for a range of conditions, including pain, infertility, embryo quality, autism, rheumatoid arthritis, psoriatic arthritis, fetal heart disease, and COVID-19. By translating biological discoveries into actionable insights, the company seeks to enhance patient care and improve outcomes in various medical fields.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Sumaq Life is a technology company specializing in AI-driven healthcare solutions. It focuses on identifying cancer patients eligible for genomic testing by integrating with electronic medical records. The company then employs gene regulatory modeling to develop personalized treatment plans, targeting therapy for a higher chance of success across various aggressive cancer types.

Plastomics Inc. is a biotechnology company specializing in chloroplast genetic engineering to enhance crop performance. Founded in 2016 and based in St. Louis, Missouri, the company focuses on gene stacking and rapid breeding to improve yield production and nutritional quality. Its innovative technology platform allows for the precise insertion of beneficial traits into the chloroplasts of plant cells, facilitating the development of more effective biotech crops. This approach not only addresses current industry challenges but also eliminates cross-pollination, enabling clients to achieve trait expression in plants more reliably. Additionally, Plastomics' unique method of maternal inheritance streamlines breeding timelines and reduces costs, making it a valuable partner for seed companies in the agricultural sector.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Inso Biosciences is an early-stage biotechnology company focused on developing innovative hardware platforms and tools for genomic sample handling. Utilizing patented microfluidic technology originally created at Cornell University, the company specializes in high-efficiency processing of cellular material. Inso Biosciences aims to enhance applications in long-read DNA extraction, multiomic sample processing, and pathogen surveillance. Their platform facilitates the separation and isolation of cellular components, thereby supporting healthcare and biotech companies in their biological sample preparation needs.

Yesse Technologies develops a genetic biosensing platform that aims to digitize the sense of smell. The company specializes in biotechnological innovations, utilizing transgenic animals and molecular biology techniques to create super sniffer mice. This unique approach enables the construction of a live, human nose-on-a-chip, which is designed to detect and identify a wide range of odors, from fragrances in perfumery to scents associated with diseases. By merging biological insights with advanced nanotechnology, Yesse Technologies seeks to revolutionize olfaction, allowing users to explore and quantify every smell on the planet.

Design Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative therapies for degenerative disorders linked to nucleotide repeat expansions. Founded in 2017 and headquartered in Solana Beach, California, the company is advancing its lead program aimed at treating Friedreich’s ataxia. Additionally, Design Therapeutics is exploring treatments for other conditions such as Fragile X syndrome and myotonic dystrophy, utilizing its proprietary GeneTACTM technology, which involves small-molecule gene-targeted therapeutics designed to modify the underlying causes of these inherited diseases. The company is committed to addressing serious monogenic disorders driven by nucleotide repeat mutations through its ongoing research and development efforts.

Ansa Biotechnologies, Inc. is a biotechnology company based in Berkeley, California, focused on developing innovative DNA synthesis technology utilizing enzymes. Established in 2018, the company aims to improve upon traditional chemical methods of DNA synthesis that have remained largely unchanged for decades. Ansa's enzymatic approach offers significant advantages, including increased speed, accuracy, and cleanliness in the production of DNA fragments such as oligonucleotides. This technology enhances the capabilities of biological research, therapeutics, diagnostics, and biomanufacturing by enabling the synthesis of gene-length oligonucleotides. Through its advancements, Ansa Biotechnologies seeks to facilitate innovation in the fields of biological research and engineering, ultimately providing valuable services to medical researchers and contributing to the broader biotechnology landscape.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

DNALite Therapeutics, Inc. is a biopharmaceutical company focused on developing gene therapy treatments specifically for the gastrointestinal tract. Founded in 2016 and based in San Francisco, California, DNALite utilizes innovative oral lipid nanoparticle technology to deliver mRNA and pDNA directly to intestinal stem cells. This approach targets the underlying causes of diseases such as Familial Adenomatous Polyposis, a hereditary form of colorectal cancer that often necessitates invasive surgeries in adolescents. By enabling the intestinal tract to secrete therapeutic proteins into the bloodstream, DNALite aims to transform conventional protein biologics into oral medications, potentially improving patient outcomes and accessibility to treatment.

Rumi Scientific is a research-oriented company focused on developing innovative medications and treatments for genetic disorders affecting the central nervous system, particularly Huntington's Disease. The company utilizes a proprietary human organoid platform that simulates human development in vitro, integrating gene editing techniques with multi-cellular self-organization to create defined diseased embryonic tissues. This advanced platform facilitates drug discovery and high-throughput screening, leveraging artificial intelligence to identify potential treatments. By emphasizing synthetic human embryology in both healthy and diseased contexts, Rumi Scientific aims to advance therapeutic options for numerous genetic conditions that currently lack effective cures. The company's approach combines single-cell, time-lapse imaging with customized analytic tools, resulting in a more efficient and cost-effective drug development process that enhances treatment success rates and outcomes for patients.

GenEdit Inc., founded in 2016 and based in Berkeley, California, focuses on advancing gene therapy through its innovative genome editing tools, particularly the CRISPR/Cas9 system. The company aims to address the challenges associated with gene therapy delivery by utilizing its proprietary NanoGalaxy™ platform, which systematically screens a library of nanoparticles to enhance the safety and efficiency of delivering genetic material to target tissues. GenEdit's technology is designed to facilitate therapeutic gene editing, offering a solution that is easier, faster, and more accurate than traditional methods. This positions GenEdit to potentially enable the treatment of previously incurable genetic diseases, significantly contributing to the future of non-viral, gene editing-based therapeutics.

Cornerstone Genomics, established in 2017 and based in Frederick, Maryland, specializes in providing expert guidance on the application of genomic tools in human disease research, biomedicine, veterinary sciences, and wildlife conservation. The company operates a biotechnology platform that houses proprietary DNA and protein sequence databases, along with applications designed to meticulously filter, annotate, and predict the functional impact of genetic variants. This precision enables researchers to accurately identify disease-causing genetic changes, facilitating the development of targeted therapies and gene therapies for inherited diseases.

Soil Culture Solutions, LLC, founded in 2014 and headquartered in Tampa, Florida, specializes in innovative genetic alteration technology. The company focuses on developing citrus trees that utilize CRISPR editing techniques to enhance resistance to severe diseases affecting the citrus industry. Soil Culture Solutions holds exclusive licenses to patents from community universities, enabling it to employ precision breeding methods to combat these critical infections in citrus crops.

GRO Biosciences is focused on developing advanced protein therapeutics by utilizing innovative technologies in computational protein design and synthetic biology. The company has created several genomically recoded strains of bacteria that enable the incorporation of non-standard amino acids into proteins. This approach enhances the potency, stability, and targeted delivery of these therapeutics. GRO Biosciences aims to apply its technology to improve treatments for a range of conditions, including diabetes, growth disorders, and autoimmunity, thereby addressing significant unmet medical needs.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Parabricks specializes in high-performance genomic analysis software that leverages GPU acceleration and machine learning to enable rapid processing of next-generation sequencing data. The company's technology allows for whole human genome sequencing in under an hour, significantly reducing the time and cost associated with genomic analysis. By providing fast, efficient, and low-cost solutions for genomic data processing, Parabricks enhances the throughput of healthcare facilities, facilitating personalized treatment based on individual genomic variations. This innovative approach has the potential to transform healthcare practices by improving the speed and efficiency of genetic analysis, ultimately leading to better patient outcomes.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

A-Alpha Bio, Inc. is a biotechnology company based in Seattle, Washington, established in 2017. The company specializes in synthetic biology, offering a platform known as AlphaSeq, which assists pharmaceutical companies in the development of drugs that interact with multiple targets. A-Alpha Bio provides cell-based tools for high-throughput and quantitative measurements of protein interactions, facilitating target discovery, library screening, and preclinical drug characterization. Its proprietary technology enables the mapping of protein-protein interactions at a large scale, allowing for the identification and quantification of interactions among thousands of protein pairs simultaneously. By delivering detailed maps of these interactions, A-Alpha Bio helps researchers identify potential drug targets and understand disease mechanisms, thereby streamlining the therapeutic discovery process and improving the efficiency of drug development. The company comprises a team of experts in synthetic biology, structural biology, and next-generation sequencing, focused on overcoming challenges in the drug development pipeline.

Parabricks specializes in high-performance genomic analysis software that leverages GPU acceleration and machine learning to enable rapid processing of next-generation sequencing data. The company's technology allows for whole human genome sequencing in under an hour, significantly reducing the time and cost associated with genomic analysis. By providing fast, efficient, and low-cost solutions for genomic data processing, Parabricks enhances the throughput of healthcare facilities, facilitating personalized treatment based on individual genomic variations. This innovative approach has the potential to transform healthcare practices by improving the speed and efficiency of genetic analysis, ultimately leading to better patient outcomes.

Kytopen, established in 2017 and based in Cambridge, Massachusetts, specializes in the development of a cell therapy platform. This platform facilitates the non-viral delivery of molecules into challenging-to-transfect immune cells, making the process easier, faster, and more cost-effective. The company's proprietary Flowfect™ technology combines microfluidics and automation, enabling researchers to explore new biological discoveries and develop more affordable cell and gene therapies.

Senti Bio, established in 2016 and headquartered in South San Francisco, specializes in synthetic biotechnology for therapeutic development. The company's core focus is engineering gene circuits, a platform technology that enables precise control over cellular behavior. Senti Bio's innovative approach allows for the creation of therapies with enhanced specificity and control, particularly in oncology. Their product pipeline includes SENTI-202, an off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells while sparing healthy bone marrow, and SENTI-301A, a treatment for hepatocellular carcinoma.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

CrossLife Technologies is a life science company focused on developing and commercializing molecular diagnostics for both infectious and non-communicable diseases. The firm specializes in creating diagnostic tools based on genetic material, particularly nucleic acids and DNA. Their technologies enable the direct detection of infectious pathogens from various sample types, eliminating the need for complex sample preparation or specialized instrumentation. CrossLife Technologies aims to reduce suffering and improve health outcomes by providing accurate diagnostic solutions for diseases such as HIV, malaria, chikungunya, and influenza.

Yesse Technologies develops a genetic biosensing platform that aims to digitize the sense of smell. The company specializes in biotechnological innovations, utilizing transgenic animals and molecular biology techniques to create super sniffer mice. This unique approach enables the construction of a live, human nose-on-a-chip, which is designed to detect and identify a wide range of odors, from fragrances in perfumery to scents associated with diseases. By merging biological insights with advanced nanotechnology, Yesse Technologies seeks to revolutionize olfaction, allowing users to explore and quantify every smell on the planet.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Navipoint Genomics is a bioinformatics analysis software company based in Chicago, Illinois, founded in 2015. The company specializes in developing software that enables the rapid analysis of entire human genomes, facilitating large-scale genomic studies. Its technology streamlines the transfer and examination of genomic data, significantly reducing analysis time while enhancing the ability to detect gene expression changes and fusion transcripts at the whole-transcriptome level. This advanced capability allows clients to achieve higher reporting quality with increased confidence and fewer false negatives in their genomic analyses.

Varigen Biosciences is developing new technologies for capturing and expressing natural product pathways. Learn about our DNAtrap™ custom cloning service which delivers verified clones of your DNA target (up to 100 kb) in just 10 days at http://varigenbiosciences.com/dnatrap-custom-cloning-service/. Learn about how our BigDNA™ metagenomics libraries can revolutionize natural product discovery at http://varigenbiosciences.com/products/.

Parabricks specializes in high-performance genomic analysis software that leverages GPU acceleration and machine learning to enable rapid processing of next-generation sequencing data. The company's technology allows for whole human genome sequencing in under an hour, significantly reducing the time and cost associated with genomic analysis. By providing fast, efficient, and low-cost solutions for genomic data processing, Parabricks enhances the throughput of healthcare facilities, facilitating personalized treatment based on individual genomic variations. This innovative approach has the potential to transform healthcare practices by improving the speed and efficiency of genetic analysis, ultimately leading to better patient outcomes.

enEvolv, Inc. specializes in engineering and licensing microorganisms, including bacteria, yeast, and algae, to produce chemicals, enzymes, and small molecules for various industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals. Founded in 2011 and based in Boston, Massachusetts, enEvolv addresses the growing global demand for essential resources due to population growth and economic development. The company collaborates with other businesses to engineer novel microorganisms and enhance existing strains, aiming to increase production yield and product quality. Utilizing its proprietary genome engineering platform, which employs Multiplex Automated Genome Engineering (MAGE) technology developed at Harvard, enEvolv accelerates the evolution of living cells, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

BioInfoExperts specializes in comprehensive molecular surveillance services aimed at understanding infectious disease dynamics and monitoring pathogens. The company offers a range of services, including genomic sequencing, RNA and DNA extraction, data analytics, and cloud-based data visualization. These services are designed to support clients in researching and developing various diagnostic tests while providing essential laboratory capabilities. Through its expertise, BioInfoExperts contributes to advancements in the field of infectious disease management and pathogen tracking.

Novome Biotechnologies, Inc. is a biotechnology company that focuses on engineering bacteria from the human gut to develop innovative treatments for chronic diseases. Its proprietary platform, which allows for the controlled colonization of the gut with genetically engineered microbial medicines (GEMMs), is designed to provide sustained therapeutic effects. Novome's lead preclinical program targets hyperoxaluria by developing a therapeutic strain of bacteria that degrades oxalate, thereby preventing kidney stone formation. The company aims to leverage its synthetic biology tools to expand its applications into additional health conditions, enhancing its ability to deliver precise therapeutic activities through engineered gut microbiota. Founded in 2015, Novome is headquartered in South San Francisco, California.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, primarily sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics enables the rapid development of new products, helping various industries reduce costs and accelerate product innovation. Its focus on sustainable chemistry positions the company as a key player in advancing environmentally friendly manufacturing processes.

T3S Technologies, Inc., established in 2015 and located in Salt Lake City, Utah, specializes in the production of proteins from bacteria. The company utilizes its expertise in genetics and biochemistry, along with proprietary technologies, to genetically engineer bacterial cells. This enables the expression and optimization of challenging recombinant protein products. T3S Technologies' innovations facilitate protein production, which supports researchers in their efforts to develop treatments for chronic diseases.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

Serotiny, Inc. is a biotechnology company based in San Francisco that specializes in the design and development of multi-domain proteins and therapies for cancer and genetic disorders. Founded in 2014, the company leverages a combination of synthetic biology and advanced informatics to create innovative therapeutic proteins, particularly for CAR T-cell therapies. Its platform integrates computational protein design, high-throughput cellular assays, and next-generation sequencing to engineer complex proteins effectively. By applying expertise from various fields such as immunology, machine learning, and bioinformatics, Serotiny aims to enhance the safety and efficacy of gene and cell therapies through novel control methods and engineered functionalities.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Aperiomics, Inc. is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services for the animal screening, agricultural testing, and human diagnostics industries. Founded in 2013 and initially known as NextGen Diagnostics, the company changed its name in 2014. Aperiomics utilizes advanced sequencing technologies and a proprietary informatics pipeline to identify a wide range of pathogens, including viral, bacterial, fungal, and parasitic organisms, through a single test. By employing Deep Shotgun Metagenomic Sequencing and leveraging a comprehensive database of over 37,000 microbes, Aperiomics enables medical professionals to identify infections that may be missed by conventional testing methods. This innovative approach has aided many patients suffering from unexplained illnesses by providing accurate diagnoses and facilitating effective treatment pathways. Recognized for its contributions to the field, Aperiomics received accolades such as Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018.

Epicrop Technologies, Inc. is a biotechnology company based in Lincoln, Nebraska, founded in 2013. It specializes in developing epigenetic technology aimed at enhancing crop yields across all plant species. The company's innovative approach focuses on improving crop development and increasing tolerance to abiotic stressors, which are environmental factors that can adversely affect plant growth. By applying these epigenetic methods, Epicrop enables farmers to boost their crop yields while maintaining lower prices, ultimately supporting agricultural productivity and sustainability.

Knudra Transgenics, LLC is a biotechnology company based in Murray, Utah, specializing in the research, development, and production of DNA mixes and plasmids for the biomedical industry. Founded in 2009, Knudra offers custom transgenics production services, primarily focusing on the model organism Caenorhabditis elegans (C. elegans). The company also provides a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms following the injection of external reagents. As a subsidiary of NemaMetrix, Inc., Knudra Transgenics plays a significant role in advancing genetic research and applications in the life sciences sector.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Mission Bio, Inc. is a biotechnology company that specializes in tools for studying cellular heterogeneity in human health and life sciences. The company has developed the Tapestri Platform, the first single-cell multi-omics platform, which allows for the simultaneous analysis of genotype and phenotype from the same cell. This platform utilizes proprietary microfluidic droplet technology to enable precise detection of genomic variability at single-cell resolution, facilitating research in various applications, including oncology, blood cancers, solid tumors, and genome editing. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating customized single-cell DNA panels, further enhancing its capabilities in targeted molecular analysis. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.

GlobalBio specializes in therapeutic antibody engineering. The company, which was founded in 2014 with funds from the National Science Foundation, is based in Brookline, Massachusetts.

enEvolv, Inc. specializes in engineering and licensing microorganisms, including bacteria, yeast, and algae, to produce chemicals, enzymes, and small molecules for various industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals. Founded in 2011 and based in Boston, Massachusetts, enEvolv addresses the growing global demand for essential resources due to population growth and economic development. The company collaborates with other businesses to engineer novel microorganisms and enhance existing strains, aiming to increase production yield and product quality. Utilizing its proprietary genome engineering platform, which employs Multiplex Automated Genome Engineering (MAGE) technology developed at Harvard, enEvolv accelerates the evolution of living cells, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

TeselaGen Biotechnology, established in 2011 and headquartered in San Francisco, specializes in DNA design and assembly tools for biological research. The company provides a cloud-based solution enabling combinatorial gene design and editing, which includes tools for visualizing, editing, and annotating genetic sequences, constructing novel gene constructs, optimizing assembly protocols, and validating design variants.

Insilicom provides advanced next-generation sequencing data analysis solutions for cancer research biomarker discovery. The company was founded in 2013 and is headquartered in Tallahassee, Florida.

Advirna is a private biotechnology company focused on developing innovative solutions for the efficient delivery of polynucleotides in vivo, particularly through its self-deliverable RNA interference (RNAi) technology. This cutting-edge approach leverages recent breakthroughs in biology to enable precise regulation of gene activity within living cells. Advirna's technology facilitates the effective knockdown of genes in challenging cell lines both ex vivo and in vivo, allowing for the efficient delivery of RNAi across various cell types and specific organs. By enhancing the ability to study and manipulate gene activity, Advirna aims to advance research capabilities in the field of molecular biology.

Parabon NanoLabs Inc. is a biotechnology company based in Reston, Virginia, specializing in the development of innovative therapeutic and forensic products using advanced DNA technology. The company designs multi-functional macromolecules aimed at treating various cancers, including brain, lung, and breast cancer. In addition to therapeutics, Parabon NanoLabs creates and licenses macromolecules for applications in bioweapons defense, DNA biometrics, and consumer product enhancements. Their expertise spans areas such as bioinformatics, oncology, chemistry, and computer science, allowing them to leverage recent advancements in DNA sequencing and processing technologies. Parabon NanoLabs also offers custom design and fabrication services, positioning itself as a vertically integrated player in the healthcare technology sector. As a small business recognized by the U.S. Small Business Administration, it has received multiple grants for innovation in its field.

Aperiomics, Inc. is a biotechnology company based in Sterling, Virginia, specializing in pathogen detection services for the animal screening, agricultural testing, and human diagnostics industries. Founded in 2013 and initially known as NextGen Diagnostics, the company changed its name in 2014. Aperiomics utilizes advanced sequencing technologies and a proprietary informatics pipeline to identify a wide range of pathogens, including viral, bacterial, fungal, and parasitic organisms, through a single test. By employing Deep Shotgun Metagenomic Sequencing and leveraging a comprehensive database of over 37,000 microbes, Aperiomics enables medical professionals to identify infections that may be missed by conventional testing methods. This innovative approach has aided many patients suffering from unexplained illnesses by providing accurate diagnoses and facilitating effective treatment pathways. Recognized for its contributions to the field, Aperiomics received accolades such as Life Science Innovator of the Year in 2016 and International Start Up of the Year in 2018.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, primarily sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics enables the rapid development of new products, helping various industries reduce costs and accelerate product innovation. Its focus on sustainable chemistry positions the company as a key player in advancing environmentally friendly manufacturing processes.

Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Molecular Assemblies, Inc. is a San Diego-based company specializing in enzymatic DNA synthesis technology, which facilitates the development of DNA-based products across various industries. Founded in 2013, the company focuses on creating long, high-quality, sequence-specific DNA in a reliable, affordable, and sustainable manner, inspired by natural processes. Its technology has applications in industrial synthetic biology, personalized therapeutics, precision diagnostics, information storage, nanotechnology, and DNA electronics. The firm boasts a skilled executive and scientific team, supported by a robust intellectual property portfolio. Molecular Assemblies has garnered investments from a range of venture capital sources, indicating strong interest in its innovative approach to DNA synthesis.

The J. Craig Venter Institute is a prominent organization in genomic research, established in October 2006 through the merger of several institutions, including The Institute for Genomic Research and The Center for the Advancement of Genomics. With over 400 scientists and staff, the Institute operates from two primary locations in Rockville, Maryland, and San Diego, California, encompassing more than 250,000 square feet of laboratory space. The Institute's research initiatives span a wide range of topics, including genomic medicine, infectious diseases, mammalian genomics, microbial and environmental genomics, and synthetic biology. Notable achievements include the sequencing of the first free-living organism and significant contributions to the human genome project. Recent projects have involved sequencing microbial flora in human environments and discovering millions of new genes from ocean sampling expeditions. The Institute is also actively engaged in creating synthetic organisms and studying the evolution of infectious disease agents, aiming to enhance understanding and treatment of various diseases affecting global health.

Protabit specializes in protein engineering for various sectors, including industrial, agricultural, and healthcare applications. The company employs a unique platform technology that integrates computational modeling with high-throughput screening and directed evolution to enhance the diversity of protein sequences. This innovative approach allows Protabit to produce novel proteins tailored to specific needs. The development of their technology is supported by strategic partnerships with notable organizations, including Monsanto Company and the California Institute of Technology. Through its advanced methodologies, Protabit aims to advance the field of protein design and provide customized solutions for its clients.

Benson Hill is an agricultural technology company that specializes in crop improvement and soy protein innovation. The company focuses on unlocking the natural genetic diversity of plants to develop healthier, more sustainable food and ingredients. Its proprietary CropOS platform leverages machine learning and big data alongside traditional breeding techniques to streamline and expedite the product development process. Benson Hill operates a Crop Accelerator designed for rapid prototyping and is actively developing a seed portfolio that includes protein ingredients, aquaculture, specialty animal feed, and vegetable oils. The company generates revenue from both proprietary and non-proprietary product categories, with proprietary revenue stemming from the sale of its unique bean varieties.

Inscent is a technology development, gene discovery, and functional genomics company that identified novel molecules to control insect pests. Key areas of interest include the prevention of disease transmission to humans and the development of environmentally friendly products for public health, agricultural, domestic, and industrial applications.

Caribou Biosciences, Inc. is a biotechnology company based in Berkeley, California, that specializes in cellular engineering and genome editing solutions using CRISPR technology. Incorporated in 2011, the company has developed a CRISPR-Cas gene editing platform that allows precise modifications to DNA, which is applicable across various fields including human and animal therapeutics, agricultural biotechnology, and industrial biotech. Caribou's innovative approach aims to create transformative therapies, particularly in the development of allogeneic CAR-T and CAR-NK cell therapies, targeting serious diseases. The company focuses on advancing its pipeline of next-generation genome-edited cell therapies while also contributing to basic and applied biological research.

Knudra Transgenics, LLC is a biotechnology company based in Murray, Utah, specializing in the research, development, and production of DNA mixes and plasmids for the biomedical industry. Founded in 2009, Knudra offers custom transgenics production services, primarily focusing on the model organism Caenorhabditis elegans (C. elegans). The company also provides a cloud-based genome engineering platform that enables biotechnologists to test the genome compositions of various organisms following the injection of external reagents. As a subsidiary of NemaMetrix, Inc., Knudra Transgenics plays a significant role in advancing genetic research and applications in the life sciences sector.

Arcadia Biosciences, Inc. is an agricultural technology company based in Davis, California, focusing on the development of crop productivity traits primarily in hemp, wheat, and soybean. Established in 2002, the company employs advanced screening, breeding, and biotechnology techniques to create products that enhance farm economics and improve the value of crops as food ingredients, health and wellness products, and for industrial applications. Its product lineup includes GoodHemp, a range of non-GMO hemp seed varieties aimed at genetic improvement; GoodWheat, which transforms wheat into a functional food; and a drought and herbicide-tolerant soybean trait known as HB4. Additionally, Arcadia Biosciences produces plant-based food and beverage products, including high-fiber pasta and coconut water, thereby catering to consumer demands while promoting environmental sustainability. The company operates in diverse markets, including the United States, Canada, Africa, and India, and collaborates with several industry partners to advance its initiatives.

enEvolv, Inc. specializes in engineering and licensing microorganisms, including bacteria, yeast, and algae, to produce chemicals, enzymes, and small molecules for various industries such as specialty chemicals, food, energy, personal care, and pharmaceuticals. Founded in 2011 and based in Boston, Massachusetts, enEvolv addresses the growing global demand for essential resources due to population growth and economic development. The company collaborates with other businesses to engineer novel microorganisms and enhance existing strains, aiming to increase production yield and product quality. Utilizing its proprietary genome engineering platform, which employs Multiplex Automated Genome Engineering (MAGE) technology developed at Harvard, enEvolv accelerates the evolution of living cells, offering significant advantages in speed, cost, and engineering capabilities. As of March 2020, enEvolv operates as a subsidiary of Zymergen, Inc.

Primordial Genetics Inc. is a biotechnology company based in San Diego, California, founded in 2011. The company specializes in the development of microbes and enzymes for use in pharmaceutical and industrial manufacturing, as well as agriculture. It utilizes whole-genome synthetic biology tools to create organisms and enzymes for diverse applications. One of its key innovations is the Function Generator, a combinatorial gain-of-function technology that enhances the tolerances and productivity of microbial organisms. This technology facilitates the rapid development of new biological products and traits necessary for the microbial production of amino acids, proteins, chemicals, and other valuable compounds. Primordial Genetics' solutions have potential applications across various sectors, including therapeutic protein production, renewable fuels, and natural product discovery.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Digital World Biology develops and sells mobile applications and instructional materials that allow students to conduct molecular biology research. The apps can be used by elementary school students to work with DNA structures and molecules. They bring bioinformatics out of the lab and into the classroom. The company also provides professional development for college instructors and school teachers, as a genomics consulting service.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.

Da Yu Protein Sciences is a research driven biotechnology company developing technologies and services for drug discovery and the bioprocessing industry. Their client base includes biopharmaceutical companies, pharmaceutical companies, and research organizations pursuing drug discovery and development.

Modular Genetics, Inc. is a biotechnology company based in Woburn, Massachusetts, founded in 2000. The company specializes in designing and developing engineered microorganisms that synthesize chemicals from renewable raw materials, primarily sugar. By utilizing a proprietary automated gene engineering system, Modular Genetics enables the rapid development of new products, helping various industries reduce costs and accelerate product innovation. Its focus on sustainable chemistry positions the company as a key player in advancing environmentally friendly manufacturing processes.

Manus Bio Inc. is a biotechnology company that specializes in recreating plant processes in microorganisms to produce natural ingredients through advanced fermentation technology. Founded in 2011 and based in Cambridge, Massachusetts, the company utilizes a combination of metabolic engineering, protein engineering, and systems biology to develop microbes capable of generating a variety of plant-based ingredients. These ingredients have diverse applications, including flavors, fragrances, food ingredients, cosmetics, vitamins, pharmaceuticals, and agricultural chemicals. Manus Bio operates manufacturing facilities in Cambridge and Augusta, Georgia, and has established a strategic partnership with BBGI Public Company Limited. The company was previously known as Manus Biosynthesis, Inc. before changing its name in June 2018.

Ginkgo Bioworks is a biotechnology firm based in Boston, Massachusetts, that specializes in designing, engineering, and developing custom microbes and organisms for various applications. Founded in 2008, the company focuses on discovering and licensing molecules used in flavors, sweeteners, cosmetic ingredients, crop treatments, and pharmaceuticals. In addition to these capabilities, Ginkgo Bioworks provides probiotic bacteria that help protect against infections and creates extensive libraries of molecules. The firm operates across multiple markets, including cultured ingredients, carbon mitigation, probiotics, and natural product discovery. It has reorganized its operations into two primary segments: Cell Engineering and Biosecurity, with a significant portion of its revenue generated from biosecurity-related data analytics and services.